<!DOCTYPE html><html><head><title>Breast cancer: the proportion of patients with N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Breast cancer: the proportion of patients with N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L. Quality indicators in breast cancer care. Eur J Cancer. 2010 Sep;46(13):2344-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20675120" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the proportion of patients with N+ or N- T &gt; 1 cm human epidermal growth factor receptor 2 positive (HER2+) (immunohistochemistry [IHC] 3+ or fluorescence in situ hybridisation positive [FISH+]) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Since 1990, in the United States and many European countries, breast cancer mortality is decreasing by 1% to 2% per year, thanks to early detection and improved treatment. However, it has been reported that there were still wide differences in treatment offered to patients with breast cancer in terms of mastectomy and radiotherapy rates and use of adjuvant chemotherapy and hormone therapy. It has also been shown that the specialised breast cancer care was associated with a significant reduction in mortality. Breast cancer care is complex, onerous and expensive; therefore, quality measurements are essential to monitor effectiveness and to guide improvements in healthcare.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>Cataliotti L, Costa A, Daly PA, Fallowfield L, Freilich G, Holmberg L, Piccart M, van de Velde CJ, Veronesi U. Florence statement on breast cancer, 1998 forging the way ahead for more research on and better care in breast cancer. Eur J Cancer. 1999 Jan;35(1):14-5. [0 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10211082" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L. Quality indicators in breast cancer care. Eur J Cancer. 2010 Sep;46(13):2344-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20675120" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. BMJ. 1996 Jan 20;312(7024):145-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8563532" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Grilli R, Minozzi S, Tinazzi A, Labianca R, Sheldon TA, Liberati A. Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. Ann Oncol. 1998 Apr;9(4):365-74. [61 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9636826" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Sainsbury R, Rider L, Smith A, MacAdam A. Does it matter where you live? Treatment variation for breast cancer in Yorkshire. The Yorkshire Breast Cancer Group. Br J Cancer. 1995 Jun;71(6):1275-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7779723" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Schachter HM, Mamaladze V, Lewin G, Graham ID, Brouwers M, Sampson M, Morrison A, Zhang L, O'Blenis P, Garritty C. Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer. 2006;6:291. [28 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17176480" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Vulto JC, Louwman WJ, Poortmans PM, Lybeert LM, Rutten HJ, Coebergh JW. A population based study of radiotherapy in a cohort of patients with breast cancer diagnosed between 1996 and 2000. Eur J Cancer. 2007 Sep;43(13):1976-82. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17618112" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Breast cancer; human epidermal growth factor receptor 2 positive (HER2+) (immunohistochemistry [IHC] 3+ or fluorescence in situ hybridisation positive [FISH+]) invasive carcinoma; chemotherapy; adjuvant trastuzumab</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Number of patients with a diagnosis of N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Number of patients with a diagnosis of N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li><em>Motivation</em>: Trastuzumab should be offered to patients with HER2+ (IHC 3+ or fluorescence in situ hybridization [FISH]+) invasive breast cancer N+ or N- T &gt; 1 cm if they receive adjuvant chemotherapy. It is recommended to follow the American Society of Clinical Oncology (ASCO) guidelines for HER2 testing. </li>
    <li><em>Level of evidence</em>: I*. Clinical trials have shown that adjuvant trastuzumab improves relapse-free survival (RFS) and overall survival (OS) in patients with N+ or N- T &gt; 1 cm HER2+ early breast cancer above chemotherapy alone. </li>
</ul>
<p class="Note">*Graded according to the short version of the U.S. Agency for Healthcare Research and Quality (AHRQ) classification. For more information regarding the developer's methodology, refer to the original source document.</p>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<table><tr><td>Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L. Quality indicators in breast cancer care. Eur J Cancer. 2010 Sep;46(13):2344-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20675120" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>
<div class='FieldValue'>
Ambulatory Procedure/Imaging Center
</div>
<div class='FieldValue'>
Hospital Inpatient
</div>
<div class='FieldValue'>
Hospital Outpatient
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Single Health Care Delivery or Public Health Organizations
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Getting Better
</div>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Therapeutic Intervention
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Number of patients with a diagnosis of N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+)* invasive carcinoma treated with chemotherapy</p>
<p class="Note">*<strong>Note</strong>:</p>
<ul class="Note" style="list-style-type: disc;">
    <li>N = node </li>
    <li>T = tumour </li>
    <li>HER2 = human epidermal growth factor receptor 2 </li>
    <li>IHC = immunohistochemistry </li>
    <li>FISH = fluorescence in situ hybridisation </li>
</ul>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Number of patients with a diagnosis of N+ or N- T &gt; 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Paper medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Prescriptive Standard
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Minimum standard: 80% </li>
    <li>Target: greater than 90% </li>
</ul>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Prescriptive Standard
</h3>
<div class='FieldValue'>
<table><tr><td>Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L. Quality indicators in breast cancer care. Eur J Cancer. 2010 Sep;46(13):2344-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20675120" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>13b: Appropriate chemotherapy and other medical therapy.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Quality Indicators in Breast Cancer Care
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
European Society of Breast Cancer Specialists - Clinical Specialty Collaboration
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
European Society of Breast Cancer Specialists - Clinical Specialty Collaboration
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>European Society of Breast Cancer Specialists (EUSOMA)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>M. Rosselli Del Turco (EUSOMA, Florence, Italy); A. Ponti (CPO Piemonte, Turin, Italy); U. Bick (Charit&eacute; &ndash; Universit&auml;tsmedizin Berlin, Berlin, Germany); L. Biganzoli (Hospital of Prato, Prato, Italy); G. Cserni (Bacs-Kiskun County Teaching Hospital, Kecskem&eacute;t, Hungary); B. Cutuli (Policlinique de Courlancy, Reims, France); T. Decker (Dietrich Bonhoefer Clinic, Neubrandeburg, Germany); M. Dietel (Charit&eacute; &ndash; Universit&auml;tsmedizin Berlin, Berlin, Germany); O. Gentilini (European Institute of Oncology, Milan, Italy); T. Kuehn (Klinikum Esslingen, Esslingen, DE, Germany); M.P. Mano (AOU San Giovanni Battista, Turin, Italy); P. Mantellini (Istituto per lo Studio e la Prevenzione Oncologica, ISPO, Florence, Italy); L. Marotti (EUSOMA, Florence, Italy); P. Poortmans (Institute Verbeeten, Tilburg, The Netherlands); F. Rank (Rigshospitalet, Copenhagen, Denmark); H. Roe (North Cumbria University Hospitals NHS Trust, Cumbria, United Kingdom); E. Scaffidi (European Institute of Oncology, Milan, Italy); J.A. van der Hage (National Cancer Institute, Amsterdam, The Netherlands); G. Viale (European Institute of Oncology and University of Milan, Milan, Italy); C. Wells (University College London Hospitals, London, United Kingdom); M. Welnicka-Jaskiewicz; (Medical University of Gdansk, Gdansk, Poland); Y. Wengst&ouml;m (Karolinska Institutet, Stockholm, Sweden); L. Cataliotti (Careggi University Hospital, Florence, Italy)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None declared.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2010 Jun
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in January 2017.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source available from the <a href="http://www.eusoma.org/doc/guideline.recommendations.Eusoma.QI.pdf" title="EUSOMA Web site">European Society of Breast Cancer Specialists (EUSOMA) Web site</a>.</p>
<p>For more information, contact M. Rosselli Del Turco at Email: <a href="mailto:secretariat@eusoma.org">secretariat@eusoma.org</a>; Web site: <a href="http://www.eusoma.org/">www.eusoma.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on August 24, 2012. The information was verified by the measure developer on October 4, 2012. </p>
<p>The information was reaffirmed by the measure developer on January 9, 2017.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This article was published in the European Journal of Cancer, Vol. 46, Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L, Quality indicators in breast cancer care, 2344-56, Copyright Elsevier (2010). This permission is granted for non-exclusive world English rights only. For other languages please reapply separately for each one required. Permission excludes use in a print form. Should you have a specific print project in mind please reapply for permission. Reproduction of this material is confined to the purpose for which permission is hereby given.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstom Y, Cataliotti L. Quality indicators in breast cancer care. Eur J Cancer. 2010 Sep;46(13):2344-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20675120" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>